{"id":11440,"date":"2020-08-20T11:06:35","date_gmt":"2020-08-19T22:06:35","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=11440"},"modified":"2020-08-20T11:19:35","modified_gmt":"2020-08-19T22:19:35","slug":"ibrutinib-may-improve-car-t-cell-production-for-patients-with-chronic-lymphocytic-leukemia","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=11440","title":{"rendered":"Ibrutinib May Improve CAR T-Cell Production for Patients With Chronic Lymphocytic Leukemia"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″][vc_column column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ width=”1\/1″][vc_custom_heading heading_semantic=”h1″ text_size=”h1″]<\/p>\n

Ibrutinib May Improve CAR T-Cell Production for Patients With Chronic Lymphocytic Leukemia<\/h1>\n

[\/vc_custom_heading][vc_column_text]This article was originally published by Targeted Oncology<\/a><\/p>\n

Ibrutinib (Imbruvica) during chimeric antigen receptor (CAR) T-cell culture improved the yield and function of CAR T-cell products as treatment of patients with chronic lymphocytic leukemia (CLL) in a study published in the\u00a0International Journal of Cancer<\/em>.<\/p>\n

The study investigators led by Leapold Sellner, MD wrote, \u201cour study provides evidence that BTK\/ITK inhibition with ibrutinib during CAR T-cell generation may improve CLL patient-derived CAR T cell products and may have the potential to enhance CAR T-cell function. Ibrutinib-supplemented CAR T-cell production leads to increased CAR T-cell yields as well as enriches for less-differentiated T cells with lower expression of exhaustion markers and could be an option to further improve the clinical outcome of CLL patients.\u201d<\/p>\n

Sellner et al evaluated the absolute cell numbers during CAR T-cell generation by Trypan blue staining. During cell generation, cell proliferation was significantly lower in CLL-derived cells compared with HD-derived cells. The BTK inhibitor allowed for a significant increase in cell expansion of HD-derived cells on day 10 of the CAR T-cell generation (20.67 \u00b1 8.82 \u00d7 106 without ibrutinib vs. 25.28 \u00b1 10.29 \u00d7 106 with ibrutinib;\u00a0P<\/em>\u00a0=.0248), and ibrutinib appeared to significantly increase the viability of CD3-positive T cells from HDs on day 10 (3% \u00b18% vs 87% \u00b1 7%;\u00a0P<\/em>\u00a0=.0183) and day 14 (84% \u00b1 8% vs 91% \u00b1 6%, respectively;\u00a0P<\/em>\u00a0=.0202).<\/p>\n

To continue reading this article here on Targeted Oncology<\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Ibrutinib during CAR T-cell culture improved the yield and function of CAR T-cell products as treatment of patients with chronic lymphocytic leukemia.<\/p>\n","protected":false},"author":1,"featured_media":11443,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[12,17,23],"tags":[],"class_list":["post-11440","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media","category-featured","category-research"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2020\/08\/CLL-red-1.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/11440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11440"}],"version-history":[{"count":2,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/11440\/revisions"}],"predecessor-version":[{"id":11448,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/11440\/revisions\/11448"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/11443"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}